| Name | Title | Contact Details |
|---|
Cognition Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Amalgam Rx develops digital therapies that empower patients with chronic diseases to achieve better outcomes
Silicon Therapeutics is an integrated physics driven drug discovery company focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our platform closely represents the real dynamical nature of targets using accurate all-atom simulations, enabling us to design and optimize compounds for targets that were previously considered "undruggable." Our science, our team, and our mission are focused on applying advanced computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China
At PharmMD, we believe every patient deserves personalized attention, the best information available, and reliable guidance from medical professionals to live a healthier life. This deeply held conviction guided our founder Fred McWhorter, an old-fashioned pharmacist who devoted more than 50 years to his passion of bringing health and healing to his customers–not simply selling medicine. Recognizing the value of emerging technology, he envisioned building a real-time information bridge between pharmacists (Pharm) and physicians (MD) to significantly improve patient treatment. Following Fred’s untimely death in 2005, his brother Clayton McWhorter, a veteran healthcare pioneer, brought Fred’s dream to fruition. In 2006, Clayton teamed with entrepreneur Samuel “Bo” Bartholomew to establish PharmMD in Nashville, TN. With the arrival of successful healthcare executive Robert Yeager as CEO in 2013, PharmMD pressed to the forefront in Medicare Part D Star Ratings improvement, as well as Medication Therapy Management (MTM) programs. Today PharmMD remains a leader in quality improvement and a healthcare industry innovator, delivering fast and effective solutions to CMS-regulated health plans and employer groups. Our pioneering technology, proprietary protocols and personalized patient profiles, combined with our outcomes-driven reporting, provide a catalyst for effective medication decisions; ultimately upholding Fred’s vision for improving lives. We exist to create a healthier world through the most effective use of the right medication.